Overview
- 142 inspections across 124 sites are on record.
- 463 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2025-04-18.
At a glance
Inspections
142
Sites
124
Observations
463
Career since
Jan 2008
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Curium US LLC | 18 Apr 2025 | Human Drugs | On file |
| Revance Therapeutics, Inc. | 2 Jul 2021 | Human Drugs | On file |
| Revance Therapeutics, Inc. | 1 Jul 2021 | Human Drugs | |
| Bioreliance Ltd. | 22 Sep 2017 | Human Drugs | On file |
| NAMSA | 15 Sep 2017 | Human Drugs | On file |
Sites inspected
Curium US LLCNoblesville, United States1 insp.
Revance Therapeutics, Inc.Newark, United States1 insp.
Revance Therapeutics, Inc.Moffett Field, United States1 insp.
Bioreliance Ltd.Glasgow, United Kingdom1 insp.
NAMSAChasse Sur Rhone, France1 insp.
Co-investigators
Investigators who share inspections with this person.
Timothy P Lafave15 shared
Jennifer M Gogley9 shared
Marcus F Yambot7 shared
Julia Ventura7 shared
Brian P Putz7 shared
Kim L Thomas Cruse6 shared
Don H Bark5 shared
Phal K Chhun5 shared
Steven E Porter5 shared
John A Gonzalez4 shared
Full investigator report
Get the verbatim findings behind Carla J Lundi's 463 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site